Shares of Abbott Laboratories (NYSE:ABT) rise 1.7% in pre-market trading after the company reported Q2 results.
Earnings per share were down 30.49% over the past year to $0.57, which beat the estimate of $0.41.
Revenue of $7,328,000,000 decreased by 8.16% year over year, which beat the estimate of $6,750,000,000.
For 2020, the company expects adjusted earnings of "at least" $3.25 per share.
How To Listen To The Conference Call
Date: Jul 16, 2020
Time: 09:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/c9jijzmo
52-week high: $100.00
Company's 52-week low was at $61.61
Price action over last quarter: down 0.04%
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.